Clinical Trial Details
— Status: Active, not recruiting
Administrative data
NCT number |
NCT06459128 |
Other study ID # |
LC-2024Q2-01 |
Secondary ID |
|
Status |
Active, not recruiting |
Phase |
N/A
|
First received |
|
Last updated |
|
Start date |
May 21, 2024 |
Est. completion date |
July 17, 2024 |
Study information
Verified date |
June 2024 |
Source |
Limbic Limited |
Contact |
n/a |
Is FDA regulated |
No |
Health authority |
|
Study type |
Interventional
|
Clinical Trial Summary
The goal of this clinical trial is to compare two different ways of delivering cognitive
behavioral therapy (CBT) materials to people with symptoms of anxiety and depression. The
main questions it aims to answer are:
1. Do people using the app experience greater reductions in anxiety and depression symptoms
compared to those using the workbook?
2. Does the personalization offered by the app increase engagement with CBT materials
compared to the workbook?
Participants will be given access to either the Limbic Care app or an equivalent PDF workbook
and will be asked to engage with the materials for several days each week over a period of 6
weeks. Each week, participants will complete a survey about their anxiety and depression
symptoms and report any new health issues and their experiences with the materials.
Description:
Motivation
Homework is a crucial component of cognitive-behavioral therapy (CBT) as it allows patients
to actively implement therapeutic techniques and skills outside of sessions, promoting
long-term mental health improvements. However, patient engagement with CBT homework can be
challenging due to a lack of motivation, forgetfulness, or a lack of personalization, which
can hinder the overall effectiveness of the therapy and retention in a therapy program.
Design
This randomized controlled trial (RCT) aims to evaluate the efficacy, acceptability, and
safety of an AI-enabled smartphone application (Limbic Care) compared to a standard digital
workbook (PDF format) in delivering cognitive behavioral therapy (CBT) materials to
individuals with clinically significant symptoms of anxiety and/or depression. The study will
involve 500 participants, who will be randomly allocated in a 3:2 ratio to either the
intervention group (Limbic Care app) or the control group (PDF workbook).
A large cohort (~2,000 participants) will initially be screened for inclusion and exclusion
criteria. Eligible participants will be invited to participate in a baseline survey (capped
at 550 to account for attrition and reach a target of 500 participants for the final data
collection point). This survey will measure multiple validated symptom scales (e.g., for
anxiety, depression, obsessive-compulsive disorder, health anxiety disorder) and gather
subjective ratings on variables such as familiarity with CBT, previous experience with mental
health apps, preferences for apps vs. PDF workbooks, medication status, and more.
After the baseline survey, participants will be randomly allocated to one of the two
experimental arms and invited to download the app (intervention group) or to access the PDF
workbook via a weblink (control group). Over a 6-week period, participants will be asked to
engage with their assigned materials (app or workbook) for a specified number of days each
week. Weekly surveys will measure changes in anxiety (GAD-7) and depression (PHQ-9) symptoms,
as well as any new adverse health events. Additionally, engagement metrics such as time spent
using the app or viewing workbook pages will be automatically recorded.
Outcome Measures
The primary outcomes are changes in GAD-7 and PHQ-9 scores from baseline to week 6, measured
weekly. We will also use engagement (operationalised as the time spent with the materials, as
well as the number of exercises interacted with) as a primary outcome, with the aim of
investigating whether this is a mediating factor for any effect of material format (app vs
workbook) on symptom reduction.
The secondary outcome is the incidence of adverse health events, to estimate and compare the
safety of each material format.
Additional outcome measures include changes in the Work and Social Adjustment Scale (WSAS),
self-reported satisfaction and acceptability, perceived utility and effectiveness, motivation
to engage with the materials, and changes in sleep quality (measured by the Mini Sleep
Questionnaire, MSQ).
Data Analysis
Data will be analyzed using appropriate statistical methods to compare the intervention and
control groups. Primary and secondary outcomes will be analyzed using repeated measures ANOVA
or mixed-effects models, adjusting for baseline scores and potential confounders. Subgroup
analyses will be conducted to explore the effects of demographic variables on treatment
outcomes.
Ethics and Safety
The study has been approved by the UCL research ethics committee and will be conducted in
accordance with the Declaration of Helsinki. Participants' safety and confidentiality will be
prioritized throughout the study. Adverse events will be closely monitored, and participants
will have the option to withdraw from the study at any time without penalty.